SG11201903725UA - Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same - Google Patents

Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same

Info

Publication number
SG11201903725UA
SG11201903725UA SG11201903725UA SG11201903725UA SG11201903725UA SG 11201903725U A SG11201903725U A SG 11201903725UA SG 11201903725U A SG11201903725U A SG 11201903725UA SG 11201903725U A SG11201903725U A SG 11201903725UA SG 11201903725U A SG11201903725U A SG 11201903725UA
Authority
SG
Singapore
Prior art keywords
stem cells
protecting
regeneration
neural stem
inhibitor
Prior art date
Application number
SG11201903725UA
Inventor
Kang-Yell Choi
Mi-Yeon Kim
Sungho Han
Original Assignee
Shine Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shine Biopharma Inc filed Critical Shine Biopharma Inc
Publication of SG11201903725UA publication Critical patent/SG11201903725UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)

Abstract

The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK /2 inhibitor to a patient in need thereof. In the present invention, the MEK1/ 2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor. Figures Fig. 1 — Fig.20 49
SG11201903725UA 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same SG11201903725UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160158739 2016-11-25
KR20170036268 2017-03-22
PCT/KR2017/013444 WO2018097628A2 (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same

Publications (1)

Publication Number Publication Date
SG11201903725UA true SG11201903725UA (en) 2019-05-30

Family

ID=62196019

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903725UA SG11201903725UA (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
SG10202105383QA SG10202105383QA (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202105383QA SG10202105383QA (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same

Country Status (20)

Country Link
US (3) US10485802B2 (en)
EP (2) EP3800471A1 (en)
JP (2) JP6663509B2 (en)
KR (4) KR101892457B1 (en)
CN (2) CN109073634B (en)
AU (1) AU2017363804B2 (en)
BR (1) BR112019009711A2 (en)
CA (1) CA3041245C (en)
CL (1) CL2019001415A1 (en)
DK (1) DK3425390T3 (en)
ES (1) ES2848720T3 (en)
HU (1) HUE052854T2 (en)
IL (1) IL266573B (en)
MX (1) MX2019006040A (en)
MY (1) MY194462A (en)
NZ (1) NZ754020A (en)
PH (1) PH12019501143A1 (en)
SG (2) SG11201903725UA (en)
WO (1) WO2018097628A2 (en)
ZA (1) ZA201903226B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041245C (en) 2016-11-25 2022-12-06 Shine Biopharma Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
CN114364392A (en) * 2019-05-02 2022-04-15 德克萨斯大学系统董事会 Methods and compositions relating to TERT activation therapy
KR20220024161A (en) * 2019-05-22 2022-03-03 주식회사 지뉴브 Administration method and dosing regimen for the treatment of neurodegenerative diseases using trametinib and markers
CN111143763B (en) * 2019-12-13 2021-09-17 广东电网有限责任公司 Method and device for evaluating state of power equipment and storage medium thereof
KR20230004597A (en) * 2020-04-14 2023-01-06 주식회사 지뉴브 Methods and compositions for evaluating response to therapeutic agents for neurodegenerative diseases
WO2022045723A1 (en) * 2020-08-24 2022-03-03 차의과학대학교 산학협력단 Composition for promoting differentiation of neural stem cells into dopaminergic neurons
CN112695019B (en) * 2021-03-23 2021-06-25 翌圣生物科技（上海）有限公司 Reverse transcriptase mutant and application thereof
CN115322966B (en) * 2022-08-19 2024-04-16 山东大学 Batch preparation method of calcium folate nanoparticles and method for inducing differentiation of neural stem cells into cholinergic neurons

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
HUP0501110A3 (en) * 2000-08-11 2006-06-28 Cephalon Inc West Chester Odulating multiple lineage kinase proteins
JP4662719B2 (en) * 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント Immunological methods and compositions for the treatment of Alzheimer's disease
KR100519227B1 (en) 2002-08-17 2005-10-07 서해영 A method for transdifferentiating mesenchymal stem cells into neuronal cells
ES2297723T3 (en) 2004-06-11 2008-05-01 Japan Tobacco, Inc. DERIVATIVES OF 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHIDRO-2H-PIRIDO (2,3-D) PYRIMIDINE AND RELATED COMPOUNDS FOR CANCER TREATMENT.
CN101076543A (en) * 2004-10-13 2007-11-21 阿布林克斯公司 Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
JP5214971B2 (en) 2004-10-20 2013-06-19 メルク セローノ ソシエテ アノニム 3-allylaminopiperidine derivatives
JP2008522607A (en) * 2004-12-09 2008-07-03 ニューロ セラピューティクス エービー Dickkopfs and materials and methods related to neurogenesis
JP4792290B2 (en) * 2005-12-27 2011-10-12 財団法人 東京都医学総合研究所 Method for producing neural stem cells
FR2905009A1 (en) * 2006-08-18 2008-02-22 Servier Lab METHOD OF SCREENING COMPOUNDS WITH ANTI-AMYLOID PROPERTIES
KR101082484B1 (en) * 2007-11-06 2011-11-11 한국과학기술원 Method for Screening Drug for Neurodegenerative Diseases Treatment
KR20100088342A (en) * 2009-01-30 2010-08-09 연세대학교 산학협력단 Composition for stimulating differentiation of neural stem cell
JP5645816B2 (en) * 2009-05-25 2014-12-24 国立大学法人東京工業大学 Pharmaceutical composition comprising core factor related to proliferation and differentiation of central nerve cell
EP2435585A4 (en) * 2009-05-28 2013-02-20 Univ Central Florida Res Found Method of screening drugs for reversal of amyloid beta neurotoxicity
WO2011062013A1 (en) * 2009-11-18 2011-05-26 国立大学法人徳島大学 Inducer of selective differentiation into neural stem cells and/or neural precursor cells
KR101211610B1 (en) 2010-05-10 2012-12-12 주식회사 스템폰즈 Generation composition for induced pluripotent stem cells with Bmi1, MEK inhibitor and GSK inhibitor treatment and method of manufacturing induced pluripotent stem cells using the same
KR102029391B1 (en) * 2011-12-13 2019-11-08 유니사 벤쳐스 피티와이 엘티디 Method of producing multipotent stem cells
ES2415581B2 (en) 2011-12-20 2014-02-19 Universidad Nacional De Educación A Distancia POTENTIATING COMPOUNDS OF LEARNING.
US9452215B2 (en) * 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
CN102604894B (en) * 2012-02-29 2014-07-30 中国科学院广州生物医药与健康研究院 Culture medium for preparing neural stem cells and application thereof
PL2855434T3 (en) 2012-05-30 2016-12-30 Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
CN105658788B (en) 2013-08-06 2020-07-10 武田药品工业株式会社 Method for preparing dopaminergic neurons
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US9943549B2 (en) * 2015-03-17 2018-04-17 Food Industry Research And Development Institute Isolation of human neural stem cells from amniotic fluid of patients with neural tube defects
US10179132B2 (en) 2015-05-26 2019-01-15 Industry-Academic Cooperation Foundation, Yonsei University Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same
KR20160138756A (en) 2015-05-26 2016-12-06 연세대학교 산학협력단 composition for inducing differentiation of multi-potent neural stem cell into dopaminergic meurons and method for inducing differentiation using the same
WO2017117386A1 (en) 2015-12-30 2017-07-06 Icahn School Of Medicine At Mount Sinai Methods of treating cancer using network brakes
US10744116B2 (en) 2016-03-16 2020-08-18 The Regents Of The University Of California Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas
US10731166B2 (en) 2016-03-18 2020-08-04 Caris Science, Inc. Oligonucleotide probes and uses thereof
JP7250312B2 (en) 2016-03-25 2023-04-03 エービー サイエンス Use of macitinib for the treatment of subpopulations of patients with amyotrophic lateral sclerosis
CN105816461B (en) * 2016-04-06 2018-10-30 福州大学 Application of the Trimetinib on preparing treatment parkinsonism drug
CN105796544A (en) * 2016-04-06 2016-07-27 福州大学 Application of MAPK (mitogen-activated protein kinase) signaling pathway inhibitor in preparation of PD (Parkinson's disease) treatment drug
WO2017212420A1 (en) 2016-06-07 2017-12-14 Centre For Cellular And Molecular Platforms Methods and compositions for managing neuroinflammation and neurodegeneration
CA3041245C (en) 2016-11-25 2022-12-06 Shine Biopharma Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
WO2018225063A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor

Also Published As

Publication number Publication date
MY194462A (en) 2022-11-30
WO2018097628A3 (en) 2018-08-09
ES2848720T3 (en) 2021-08-11
KR102114017B1 (en) 2020-05-22
CA3041245A1 (en) 2018-05-31
ZA201903226B (en) 2023-12-20
KR20200056465A (en) 2020-05-22
EP3800471A1 (en) 2021-04-07
MX2019006040A (en) 2019-08-21
AU2017363804A1 (en) 2019-06-20
KR102519796B1 (en) 2023-04-11
AU2017363804B2 (en) 2021-12-23
JP6663509B2 (en) 2020-03-11
EP3425390A2 (en) 2019-01-09
EP3425390A4 (en) 2019-12-25
HUE052854T2 (en) 2021-05-28
WO2018097628A2 (en) 2018-05-31
BR112019009711A2 (en) 2019-08-13
JP2020074796A (en) 2020-05-21
US10485802B2 (en) 2019-11-26
NZ754020A (en) 2022-11-25
CN115025225A (en) 2022-09-09
PH12019501143A1 (en) 2019-12-16
KR20180116235A (en) 2018-10-24
IL266573A (en) 2019-07-31
JP2019513806A (en) 2019-05-30
US20180169102A1 (en) 2018-06-21
KR20210095748A (en) 2021-08-02
US20210401844A1 (en) 2021-12-30
CA3041245C (en) 2022-12-06
US20200046706A1 (en) 2020-02-13
SG10202105383QA (en) 2021-07-29
DK3425390T3 (en) 2021-02-15
US11701360B2 (en) 2023-07-18
CL2019001415A1 (en) 2019-10-04
CN109073634B (en) 2022-07-08
US11147816B2 (en) 2021-10-19
CN109073634A (en) 2018-12-21
EP3425390B1 (en) 2020-12-23
IL266573B (en) 2022-03-01
KR101892457B1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
SG11201903725UA (en) Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
IL268327A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
BR112017008093A2 (en) processes for treating eye diseases
BR112014010803A2 (en) treatment method
JOP20200035A1 (en) Amino acid compositions for the treatment of neuronal injury
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2019246262A3 (en) Methods of treating or inhibiting onset of huntington's disease
MD3347002T2 (en) Treatment of Alzheimer's disease in a particular patient population
MX365366B (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne.
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
BR112017002637A2 (en) methods to treat or prevent eye conditions
MX2019003703A (en) Safe and effective method of treating psoriasis with anti-il23 specific antibody.
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
WO2016134257A8 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
BR112019004791A2 (en) multiple sclerosis treatment with chs-131
MX2020009532A (en) Modified oligonucleotides for use in treatment of tauopathies.
SI3694505T1 (en) Compound and composition for use in the preventive and/or curative treatment of diseases of the central nervous system characterised by a decline in neuronal plasticity, in particular characterised by a decline in synaptic plasticity
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
MX2017010873A (en) Compositions and methods for the treatment of "plaques and tangles" in humans and animals.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2019004200A (en) Combination therapy.
EA201990953A1 (en) COMPOSITION FOR THE DIFFERENTIATION AND PROTECTION OF NERVOUS STEM CELLS AND THE METHOD FOR INDUCING NEURAL REGENERATION USING THE SPECIFIED COMPOSITION